☆ 4.7 Article

Discovery of the First Potent, Selective, and In Vivo Efficacious Polo-like Kinase 4 Proteolysis Targeting Chimera Degrader for the Treatment of TRIM37-Amplified Breast Cancer

JOURNAL OF MEDICINAL CHEMISTRY (2023)

Related references

Note: Only part of the references are listed.

Article Gastroenterology & Hepatology

Polo-like kinase 4 inhibitor CFI-400945 suppresses liver cancer through cell cycle perturbation and eliciting antitumor immunity

Cerise Yuen-Ki Chan et al.

Summary: This study found that targeting the centrosome regulator PLK4 to activate the cytosolic DNA sensing-mediated immune response effectively suppressed tumor progression in late-stage mouse HCC through cell cycle inhibition and induction of antitumor immunity, presenting a durable suppressive effect.

HEPATOLOGY (2023)

Add to Collection

Article Chemistry, Medicinal

Discovery of CZS-241: A Potent, Selective, and Orally Available Polo-Like Kinase 4 Inhibitor for the Treatment of Chronic Myeloid Leukemia

Yin Sun et al.

Summary: Recent studies have identified PLK4 as a potential therapeutic target for multiple cancers due to its crucial role in cell division. This study focused on the development of a highly potent and selective PLK4 inhibitor, B43 (CZS-241), based on rational drug design strategies. B43 demonstrated effective inhibition of leukemia cells, particularly in chronic myeloid leukemia (CML) cell lines, and showed promising pharmacokinetic characteristics in mice.

JOURNAL OF MEDICINAL CHEMISTRY (2023)

Add to Collection

Article Biochemistry & Molecular Biology

The cell cycle-related genes RHAMM, AURKA, TPX2, PLK1, and PLK4 are associated with the poor prognosis of breast cancer patients

Iris Kahl et al.

Summary: This study analyzed the expression of cell cycle-related genes in breast cancer patients and correlated them with prognosis. The study found that high expression of these genes was associated with poor prognosis. Furthermore, the study also found that the expression of these genes varied in different subtypes of breast cancer. Experimental results showed that radiation could influence the expression of these genes, and knocking down or inhibiting these genes had an impact on cell cycle and colony formation. The study also identified microRNAs as potential upstream regulators of these genes, and certain microRNAs had different impacts on the prognosis of breast cancer patients. Overall, this study provides potential targets and prognostic value for the treatment and prognosis of breast cancer patients.

JOURNAL OF CELLULAR BIOCHEMISTRY (2022)

Add to Collection

Article Chemistry, Medicinal

Discovery of Potent, Selective, and In Vivo Efficacious AKT Kinase Protein Degraders via Structure-Activity Relationship Studies

Xufen Yu et al.

Summary: In this study, we reported a potent AKT degrader MS21 and its structure-activity relationship (SAR) studies. Additionally, we discovered another VHL-recruiting AKT degrader MS143 with similar efficacy as MS21, as well as a novel CRBN-recruiting PROTAC MS5033. These compounds effectively degraded AKT by hijacking the ubiquitin-proteasome system and showed significant inhibition of cell growth in multiple cancer cell lines. Furthermore, they exhibited good plasma exposure levels in mice and were suitable for in vivo studies.

JOURNAL OF MEDICINAL CHEMISTRY (2022)

Add to Collection

Review Chemistry, Medicinal

Strategies for designing proteolysis targeting chimaeras (PROTACs)

Shipeng He et al.

Summary: This review comprehensively summarizes state-of-the-art methods and strategies in the design of PROTACs, including design principles, case studies, and emerging types. It also discusses the advantages and limitations of these strategies.

MEDICINAL RESEARCH REVIEWS (2022)

Add to Collection

Article Chemistry, Medicinal

Novel CRBN-Recruiting Proteolysis-Targeting Chimeras asDegraders of Stimulator of Interferon Genes with In Vivo Anti-Inflammatory Efficacy

Jin Liu et al.

Summary: STING protein degraders offer a novel strategy for treating autoimmune and inflammatory diseases. By designing and synthesizing a series of compounds, SP23 was found to have the highest degradation potency and demonstrated strong anti-inflammatory efficacy.

JOURNAL OF MEDICINAL CHEMISTRY (2022)

Add to Collection

Article Endocrinology & Metabolism

PLK4 is upregulated in prostate cancer and its inhibition reduces centrosome amplification and causes senescence

Chandra K. Singh et al.

Summary: The role of PLK4 in prostate cancer and the prevalence of centrosome amplification (CA) were investigated in this study. The results showed that CA in prostate cancer is mainly caused by centriole overduplication, and PLK4 inhibition may be a potential therapeutic strategy for prostate cancer.

PROSTATE (2022)

Add to Collection

Article Chemistry, Medicinal

Structure-based discovery of 1-(3-fluoro-5-(5-(3-(methylsulfonyl) phenyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)phenyl)-3-(pyrimidin-5-yl)urea as a potent and selective nanomolar type-II PLK4 inhibitor

Yin Sun et al.

Summary: In this study, a potent and selective PLK4 inhibitor, compound 29u, was identified and evaluated. Further biological evaluations revealed the mechanism of compound 29u and its drug-like properties. This discovery will support the development of PLK4-targeted anticancer drugs and contribute to the understanding of PLK4 biology.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2022)

Add to Collection

Article Chemistry, Medicinal

Blocking Non-enzymatic Functions by PROTAC-Mediated Targeted Protein Degradation

Donghuan Sun et al.

Summary: The non-enzymatic functions of target proteins play crucial roles in cell signaling pathways and human diseases. PROTAC technology has emerged as a potential strategy to regulate both enzymatic and non-enzymatic functions, overcoming the limitations of traditional inhibitors.

JOURNAL OF MEDICINAL CHEMISTRY (2022)

Add to Collection

Article Chemistry, Multidisciplinary

Discovery of a Potent and Selective Degrader for USP7

Yuan Pei et al.

Summary: The selective degradation of USP7 using a PROTAC has shown promising results in inhibiting the growth of p53 mutant cancer cells, providing a potential therapeutic strategy for p53 mutant cancers.

ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2022)

Add to Collection

Article Chemistry, Medicinal

Design, synthesis, and biological evaluation of novel pyrazolo [3,4-d] pyrimidine derivatives as potent PLK4 inhibitors for the treatment of TRIM37-amplified breast cancer

Yin Sun et al.

Summary: In this study, a series of potent PLK4 inhibitors were identified through a rational drug design strategy. Compound 24j showed strong inhibitory activity against PLK4 and selectivity towards specific types of breast cancer cells and kinases. In addition, compound 24j demonstrated favorable pharmacokinetic properties in vitro and in vivo. Therefore, compound 24j holds promise as a potential lead compound for treating TRIM37-amplified breast cancer.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2022)

Add to Collection

Article Chemistry, Medicinal

Identification of novel and potent PROTACs targeting FAK for non-small cell lung cancer: Design, synthesis, and biological study

Yin Sun et al.

Summary: The intracellular non-receptor tyrosine protein kinase Focal adhesion kinase (FAK) plays a crucial role in tumor survival, invasion, metastasis, and angiogenesis. The study demonstrates the importance of addressing both FAK kinase and scaffolding functions and introduces the use of PROTAC technology to simultaneously eliminate these functions. The novel FAK PROTAC B5 exhibits potent affinity and degradation activity against FAK, as well as powerful antiproliferative effects and inhibition of cell migration and invasion. The results suggest that PROTAC B5 holds promise as a lead compound for cancer drug discovery.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2022)

Add to Collection

Review Chemistry, Multidisciplinary

Chemistries of bifunctional PROTAC degraders

Chaoguo Cao et al.

Summary: Proteolysis targeting chimeras (PROTACs) technology utilizes small molecules to induce ubiquitin-dependent degradation of proteins, offering a promising therapeutic strategy. However, the design and optimization of PROTACs face challenges, with a trial-and-error approach based on experience being the current general strategy. This review summarizes the principles and strategies for PROTACs design and optimization from the perspective of chemical structure design, and proposes potential future pathways for development.

CHEMICAL SOCIETY REVIEWS (2022)

Add to Collection

Review Chemistry, Multidisciplinary

PROTACs: past, present and future

Ke Li et al.

Summary: PROTACs are a type of molecules with novel event-driven mechanism, offering multiple advantages over traditional inhibitors, such as catalytic nature and targeted protein degradation, which may lead to improved therapeutic outcomes with reduced toxicity. However, further research and development efforts are needed to fully explore their potential.

CHEMICAL SOCIETY REVIEWS (2022)

Add to Collection

Review Biochemistry & Molecular Biology

Mitotic protein kinase-driven crosstalk of machineries for mitosis and metastasis

Chang-Hyeon Kim et al.

Summary: Accumulating evidence suggests that mitotic protein kinases play a role in both metastatic migration and tumorigenesis. Understanding the contribution of cytoskeletal proteins to cell division and metastatic motility is crucial for effective treatment of cancer metastases.

EXPERIMENTAL AND MOLECULAR MEDICINE (2022)

Add to Collection

Meeting Abstract Hematology

Targeting Polo-like Kinase 4 Triggers Polyploidy and Apoptotic Cell Death in TP53-Mutant Acute Myeloid Leukemia

Edward Ayoub et al.

BLOOD (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Targeting AURKA in Cancer: molecular mechanisms and opportunities for Cancer therapy

Ruijuan Du et al.

Summary: AURKA is overexpressed in cancers and regulates substrate functions through phosphorylation, participating in various classic oncogenic pathways.

MOLECULAR CANCER (2021)

Add to Collection

Review Oncology

Polo-Like Kinase 4's Critical Role in Cancer Development and Strategies for Plk4-Targeted Therapy

Xiaoyang Zhang et al.

Summary: Polo-like kinases (Plks) family consists of five members, with Plk4 playing a crucial role in centriole replication and being closely associated with cancer development. This review describes the molecular structure and regulation of Plk4, lists its downstream targets and cancer hallmarks, and summarizes its role in different cancers. Additionally, it reviews inhibitors targeting Plk4 for potential anticancer drug discovery.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection

Review Pharmacology & Pharmacy

Cyclin-Dependent Kinase Inhibitors and Their Therapeutic Potential in Colorectal Cancer Treatment

Oana-Maria Thoma et al.

Summary: CDKs play a key role in cell cycle regulation, with aberrant expression potentially leading to cancer development. CDK inhibitors, such as CDK4/6 inhibitors, are being investigated as novel cancer therapies.

FRONTIERS IN PHARMACOLOGY (2021)

Add to Collection

Article Chemistry, Multidisciplinary

Discovery and Characterisation of Highly Cooperative FAK-Degrading PROTACs

Robert P. Law et al.

Summary: This study introduced a novel FAK-degrading PROTAC, GSK215, designed based on VHL E3 ligase and the FAK inhibitor VS-4718, showing promising potential for a differentiated clinical strategy in cancer treatment compared to conventional FAK inhibition. The highly cooperative FAK-GSK215-VHL ternary complex revealed by X-ray crystallography provided insights into the molecular basis of the compound's efficacy. In mouse models, GSK215 demonstrated rapid and prolonged FAK degradation, highlighting its potential as a valuable tool for studying FAK-degradation biology in vivo.

ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2021)

Add to Collection

Review Pharmacology & Pharmacy

Future prospects for mitosis-targeted antitumor therapies

Alfonso Serrano-del Valle et al.

Summary: Developing new therapies targeting cell cycle regulation and mitosis has shown potential, despite many being discontinued during clinical trials. Future efforts could focus on increasing cell death signals, targeting senescent cells, and promoting antitumor immune response to enhance the efficacy of these treatments.

BIOCHEMICAL PHARMACOLOGY (2021)

Add to Collection

Article Chemistry, Medicinal

Development of Alectinib-Based PROTACs as Novel Potent Degraders of Anaplastic Lymphoma Kinase (ALK)

Shaowen Xie et al.

Summary: Novel ALK degraders based on PROTAC technology showed high specificity in ALK-positive cell lines and significant anti-tumor effects in a mouse model, indicating potential benefits for treating ALK-driven malignancies.

JOURNAL OF MEDICINAL CHEMISTRY (2021)

Add to Collection

Article Chemistry, Medicinal

Strategies toward Discovery of Potent and Orally Bioavailable Proteolysis Targeting Chimera Degraders of Androgen Receptor for the Treatment of Prostate Cancer

Xin Han et al.

Summary: This study outlines strategies for discovering highly potent PROTAC degraders of androgen receptor (AR) with excellent oral pharmacokinetics, successfully identifying compound ARD-2128 as the most effective in inhibiting tumor growth in mice with good oral bioavailability.

JOURNAL OF MEDICINAL CHEMISTRY (2021)

Add to Collection

Editorial Material Chemistry, Medicinal

PROTAC Technology: Opportunities and Challenges

Hongying Gao et al.

ACS MEDICINAL CHEMISTRY LETTERS (2020)

Add to Collection

Article Biotechnology & Applied Microbiology

MiR-654-3p Suppresses Non-Small Cell Lung Cancer Tumourigenesis by Inhibiting PLK4

Jiang-tao Pu et al.

ONCOTARGETS AND THERAPY (2020)

Add to Collection

Article Multidisciplinary Sciences

Targeting TRIM37-driven centrosome dysfunction in 17q23-amplified breast cancer

Zhong Y. Yeow et al.

NATURE (2020)

Add to Collection

Article Multidisciplinary Sciences

TRIM37 controls cancer-specific vulnerability to PLK4 inhibition

Franz Meitinger et al.

NATURE (2020)

Add to Collection

Meeting Abstract Hematology

Cfi-400945 Induces Cytokinesis Failure By Activating Hippo Signaling Pathway in Diffuse Large B-Cell Lymphoma

Yi Zhao et al.

BLOOD (2020)

Add to Collection

Review Biochemistry & Molecular Biology

Polo-like kinases and acute leukemia

Oksana Goroshchuk et al.

ONCOGENE (2019)

Add to Collection

Article Oncology

PLK4 is a determinant of temozolomide sensitivity through phosphorylation of IKBKE in glioblastoma

Zuoxin Zhang et al.

CANCER LETTERS (2019)

Add to Collection

Article Biochemistry & Molecular Biology

Evaluation of Protein Kinase Inhibitors with PLK4 Cross-Over Potential in a Pre-Clinical Model of Cancer

Amreena Suri et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)

Add to Collection

Review Oncology

PLK4: a promising target for cancer therapy

Yi Zhao et al.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2019)

Add to Collection

Article Oncology

High PLK4 expression promotes tumor progression and induces epithelial-mesenchymal transition by regulating the Wnt/-catenin signaling pathway in colorectal cancer

Zhibin Liao et al.

INTERNATIONAL JOURNAL OF ONCOLOGY (2019)

Add to Collection

Review Pharmacology & Pharmacy

PLK4: a link between centriole biogenesis and cancer

Radhika Radha Maniswami et al.

EXPERT OPINION ON THERAPEUTIC TARGETS (2018)

Add to Collection

Article Cell Biology

Polo-like kinase 4 mediates epithelial-mesenchymal transition in neuroblastoma via PI3K/Akt signaling pathway

Xiangdong Tian et al.

CELL DEATH & DISEASE (2018)

Add to Collection

Letter Multidisciplinary Sciences

CFI-400945 is not a selective cellular PLK4 inhibitor

Karen Oegema et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)

Add to Collection

Article Cell Biology

YLT-11, a novel PLK4 inhibitor, inhibits human breast cancer growth via inducing maladjusted centriole duplication and mitotic defect

Qian Lei et al.

CELL DEATH & DISEASE (2018)

Add to Collection

Article Oncology

Activity of the novel polo-like kinase 4 inhibitor CFI-400945 in pancreatic cancer patient-derived xenografts

I. Lohse et al.

ONCOTARGET (2017)

Add to Collection

Article Chemistry, Multidisciplinary

Synthesis and biological evaluation of (E)-4-(3-arylvinyl-1H-indazol-6-yl) pyrimidin-2-amine derivatives as PLK4 inhibitors for the treatment of breast cancer

Zhihao Liu et al.

RSC ADVANCES (2017)

Add to Collection

Article Multidisciplinary Sciences

Reversible centriole depletion with an inhibitor of Polo-like kinase 4

Yao Liang Wong et al.

SCIENCE (2015)

Add to Collection

Article Chemistry, Medicinal

The Discovery of Polo-Like Kinase 4 Inhibitors: Identification of (1R,2S)-2-(3((E)-4-(((cis)-2,6-Dimethylmorpholino)methyl)styryl)-1H-indazol-6-yl)-5′-methoxyspiro[cyclopropane-1,3′-indolin]-2′-one (CFI-400945) as a Potent, Orally Active Antitumor Agent

Peter B. Sampson et al.

JOURNAL OF MEDICINAL CHEMISTRY (2015)

Add to Collection

Article Biochemistry & Molecular Biology

PLK4 overexpression and its effect on centrosome regulation and chromosome stability in human gastric cancer

Kazuya Shinmura et al.

MOLECULAR BIOLOGY REPORTS (2014)

Add to Collection

Review Cell Biology

Polo-like kinases: structural variations lead to multiple functions

Sihem Zitouni et al.

NATURE REVIEWS MOLECULAR CELL BIOLOGY (2014)

Add to Collection

Article Biochemistry & Molecular Biology

Polo-like kinase 4 transcription is activated via CRE and NRF1 elements, repressed by DREAM through CDE/CHR sites and deregulated by HPV E7 protein

Martin Fischer et al.

NUCLEIC ACIDS RESEARCH (2014)

Add to Collection

Editorial Material Biochemistry & Molecular Biology

Polo-like Kinase 4 Shapes Up

Michelle S. Levine et al.

STRUCTURE (2014)

Add to Collection

Editorial Material Biochemistry & Molecular Biology

Polo Boxes Come out of the Crypt: A New View of PLK Function and Evolution

Swadhin Chandra Jana et al.

STRUCTURE (2012)

Add to Collection

Article Cell Biology

The SCF-FBXW5 E3-ubiquitin ligase is regulated by PLK4 and targets HsSAS-6 to control centrosome duplication

Anja Puklowski et al.

NATURE CELL BIOLOGY (2011)

Add to Collection

© Peeref 2019-2024. All rights reserved.